mezigdomide用于多发性骨髓瘤的III 期研究｜NCT05519085

一分钟看懂

这是一项关于多发性骨髓瘤的III 期研究，登记的药物或干预包括mezigdomide；Pomalidomide；Bortezomib；Dexamethasone，当前状态为招募中。登记地点显示中国北京、重庆、厦门、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

mezigdomide；Pomalidomide；Bortezomib；Dexamethasone · III 期

年龄范围：18岁及以上

登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。

登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

以下为摘录，请打开原始登记查看完整入排标准。

\- Participant has documented diagnosis of MM and measurable disease, defined as any of the following:.
i) M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or.
ii) M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP).
iii) For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
* Participants received 1 to 3 prior lines of antimyeloma therapy.
* Participants achieved minimal response \[MR\] or better to at least 1 prior antimyeloma therapy.
Exclusion Criteria
\- Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below:.

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT05519085；登记信息更新于 2026-09-30；本站同步于 2026-10-08。